Evofem Adds Second Phexx Manufacturing Source, Cutting Unit Costs 40%+
EVFM has more than doubled off its 52-week low of $0.001.
Summary
Evofem signed a manufacturing agreement with Zhaoke to produce Phexx, adding a second supply source expected to reduce unit costs by 40% or more. The company also plans to submit an sNDA to the FDA for Phexx in mid-2027. This follows the 8-K filed today and the 10-Q warning of insufficient cash; the cost reduction could materially improve margins if Phexx sales grow. The sNDA timeline provides a regulatory milestone to watch.
At the time of this announcement, EVFM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $1M. The 52-week trading range was $0.00 to $0.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.